UBS Group’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.3M | Sell |
557,734
-35,872
| -6% | -$1.57M | ﹤0.01% | 1696 |
|
|
2025
Q1 | $16.2M | Buy |
593,606
+123,764
| +26% | +$3.39M | ﹤0.01% | 1957 |
|
|
2024
Q4 | $18.9M | Buy |
469,842
+252,223
| +116% | +$10.1M | ﹤0.01% | 1805 |
|
|
2024
Q3 | $10.3M | Buy |
217,619
+7,318
| +3% | +$346K | ﹤0.01% | 1657 |
|
|
2024
Q2 | $6.28M | Sell |
210,301
-86,379
| -29% | -$2.58M | ﹤0.01% | 1934 |
|
|
2024
Q1 | $11.9M | Sell |
296,680
-3,783
| -1% | -$152K | ﹤0.01% | 1501 |
|
|
2023
Q4 | $7.65M | Buy |
300,463
+137,704
| +85% | +$3.51M | ﹤0.01% | 1642 |
|
|
2023
Q3 | $2.26M | Sell |
162,759
-77,957
| -32% | -$1.08M | ﹤0.01% | 2455 |
|
|
2023
Q2 | $5.53M | Buy |
240,716
+55,421
| +30% | +$1.27M | ﹤0.01% | 1814 |
|
|
2023
Q1 | $5.49M | Sell |
185,295
-17,466
| -9% | -$518K | ﹤0.01% | 1774 |
|
|
2022
Q4 | $5.06M | Buy |
202,761
+153,076
| +308% | +$3.82M | ﹤0.01% | 1832 |
|
|
2022
Q3 | $1.08M | Sell |
49,685
-61,784
| -55% | -$1.35M | ﹤0.01% | 2797 |
|
|
2022
Q2 | $2.19M | Sell |
111,469
-24,621
| -18% | -$485K | ﹤0.01% | 2331 |
|
|
2022
Q1 | $5.76M | Buy |
136,090
+66,974
| +97% | +$2.83M | ﹤0.01% | 1819 |
|
|
2021
Q4 | $4.39M | Buy |
69,116
+55,873
| +422% | +$3.55M | ﹤0.01% | 2212 |
|
|
2021
Q3 | $778K | Sell |
13,243
-13,297
| -50% | -$781K | ﹤0.01% | 3433 |
|
|
2021
Q2 | $1.29M | Buy |
26,540
+1,098
| +4% | +$53.2K | ﹤0.01% | 3061 |
|
|
2021
Q1 | $989K | Buy |
25,442
+21,829
| +604% | +$849K | ﹤0.01% | 3365 |
|
|
2020
Q4 | $224K | Buy |
3,613
+3,382
| +1,464% | +$210K | ﹤0.01% | 4208 |
|
|
2020
Q3 | $7K | Buy |
+231
| New | +$7K | ﹤0.01% | 6240 |
|